Staff Report | The Gainesville Sun
AxoGen reported record revenues of $2.86 million in the second quarter of the year, up 42 percent from $2.01 million in revenues for the second quarter of 2012 as more medical facilities used its products and existing customers used more products.
The Alachua company makes peripheral nerve repair products from human-donated tissue and trades on the Over the Counter Bulletin Board under the symbol AXGN. The stock is only available through brokers registered to deal in OTC securities.
Income for the quarter was reported as a net loss of $3.45 million, or negative $0.31 per share, compared to a net loss of $1.03 million, or $0.09 per share, in the second quarter of 2012.
CEO Karen Zaderej noted in a news release that two key products received regulatory approval in Europe and Canada.
“AxoGen continues to demonstrate that we are well positioned to capture the significant opportunity to provide off-the-shelf treatment options for patients with peripheral nerve injuries, which, we believe, will translate into continued sales growth and positive financial results,” she said.